SPINT2 deregulation in prostate carcinoma by Pereira, M. S. et al.
Journal of Histochemistry & Cytochemistry 2016, Vol. 64(1) 32 –41
© The Author(s) 2015
Reprints and permissions: 
sagepub.com/journalsPermissions.nav
DOI: 10.1369/0022155415612874
jhc.sagepub.com
Article
Introduction
Prostate carcinoma (PCa) is the most diagnosed cancer and 
the second leading cause of cancer-related death among 
men in the United States (Siegel et al. 2013). Besides the 
improvements in early detection and treatment options, 
cancer cell invasion and metastasis are the main cause of 
death in patients with PCa (Mundy et al. 2002). Therefore, 
it is important to understand and clarify the mechanisms 
involved in PCa to overcome this fatal end.
SPINT2 is a serine protease inhibitor Kunitz type 2, also 
known as hepatocyte growth factor (HGF) activator (HGFA) 
inhibitor type 2 (HAI-2). It displays inhibitory activity in 
membrane serine proteases, such as matriptase and hepsin, 
as well as secreted proteases such as HGFA and plasmin 
(Delaria et al. 1997; Marlor et al. 1997; Qin et al. 1998; 
Kirchhofer et al. 2005). Matriptase and hepsin have been 
implicated in the degradation of matrix components and 
transmembrane molecules, as well as in the modulation of 
cell-substratum adhesion (Del Rosso et al. 2002). Moreover, 
matriptase, hepsin and HGFA are able to cleave pro-HGF 
into its active form, and thus trigger the HGF/c-MET sig-
naling pathway, which is implicated in tumor growth, 
angiogenesis, invasion and metastasis (Benvenuti et al. 
2007; Owen et al. 2010).
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Summary
SPINT2 is a tumor suppressor gene that inhibits proteases implicated in cancer progression, like HGFA, hepsin and 
matriptase. Loss of SPINT2 expression in tumors has been associated with gene promoter hypermethylation; however, 
little is known about the mechanisms of SPINT2 deregulation in prostate cancer (PCa). We aimed to analyze SPINT2 
expression levels and understand the possible regulation by SPINT2 promoter hypermethylation in PCa. In a cohort 
of 57 cases including non-neoplastic and PCa tissues, SPINT2 expression and promoter methylation was analyzed by 
immunohistochemistry and methylation-specific PCR, respectively. Methylation status of the SPINT2 promoter was also 
evaluated by bisulfite sequencing and 5-aza-2’-deoxycytidine treatment. Oncomine and TCGA databases were used to 
perform in silico PCa analysis of SPINT2 mRNA and methylation levels. A reduction in SPINT2 expression levels from non-
neoplastic to PCa tissues was observed; however, none of the cases exhibited SPINT2 promoter methylation. Both bisulfite 
sequencing and 5-aza demonstrated that SPINT2 promoter is not methylated in PCa cells. Bioinformatics approaches did 
not show downregulation of SPINT2 at the mRNA level and, in corroboration with our results, SPINT2 promoter region is 
reported to be unmethylated. Our study suggests an involvement of SPINT2 in PCa tumorigenesis, probably in association 
with a post-translational regulation of SPINT2. (J Histochem Cytochem 64:32–41, 2016)
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The importance of SPINT2 in cancer malignancy has 
been highlighted in several cancer types. Low levels of 
SPINT2 have been described in ovarian carcinoma 
(Nakamura et al. 2009b), cervical cancer (Nakamura et al. 
2009a), endometrial cancer (Nakamura et al. 2011), uterine 
leiomyosarcoma (Nakamura et al. 2010) and malignant glio-
mas (Hamasuna et al. 2001). In cervical cancer, SPINT2 
downregulation is correlated with a higher tumor stage, the 
presence of lymph node involvement, and metastasis 
(Nakamura et al. 2009a). Recently, some reports indicate 
SPINT2 as a tumor suppressor gene, as hypermethylation of 
its promoter is a frequent cause of SPINT2 downregulation 
(Fukai et al. 2003; Schuster et al. 2003; Chiba et al. 2005; 
Morris et al. 2005; Kongkham et al. 2008; Morris et al. 2008; 
Tung et al. 2009; Dong et al. 2010). In PCa, a significant 
decrease of SPINT2 protein has been reported in poorly dif-
ferentiated tumors as compared with lower Gleason score 
tumors (Bergum et al. 2010; Tsai et al. 2013). However, the 
process underlying SPINT2 down-regulation in PCa is still 
unknown. Herein, we prompted to clarify the profile of 
SPINT2 expression in a series of PCa cases and examine 
whether SPINT2 promoter methylation is the mechanism 
responsible for SPINT2 downregulation. Additionally, using 
bioinformatics databases such as Oncomine and TCGA, we 
further extend and support our findings.
Materials & Methods
Tissue Samples and Cell Lines
Fifty-seven formalin-fixed paraffin-embedded (FFPE) 
prostate samples were retrieved from the Department of 
Pathology of the Alto Ave-Guimarães Hospital, Guimarães, 
Portugal. All patients are of Portuguese origin and presented 
at a median age of 63 years (range, 49–74 years). The pres-
ent study was previously approved by our local ethics 
committee.
Four PCa cell lines were used: 22RV1 (primary PCa), 
LNCaP (lymph node metastasis), PC3 (bone metastasis) 
and DU145 (brain metastasis). Human melanoma (MW9) 
and medulloblastoma (UW228) cell lines were used as con-
trols. All cell lines were cultured in RPMI with 10% fetal 
bovine serum and 1% antimitotic/antibiotic at 37°C in an 
atmosphere of 5% CO
2
.
RNA Isolation and SPINT2 Expression Analysis
Total RNA from PCa cell lines was extracted using Trizol 
reagent (Invitrogen; Carlsbad, CA) and 1 µg of RNA was 
converted into cDNA using the Phusion RT-PCR kit 
(Finnzymes; Woburn, MA), according to the manufactur-
er’s instructions. cDNA was used to determine the levels of 
SPINT2 expression using primers described by Kongkham 
and collaborators (Kongkham et al. 2008). Beta-actin was 
used to normalize expression levels (Pinto et al. 2014). 
Quantitative real time RT-PCR (RT-qPCR) was performed 
in a CFX96 detection system (Bio-Rad; Hercules, CA), 
using SSOfast Evagreen supermix (Bio-Rad) as described 
by the manufacture. Optimized cycling conditions for qPCR 
were as followed: enzyme activation for 30 sec at 95°C; 45 
cycles of denaturation at 95°C for 5 sec, and annealing/
extension for 5 sec at 59°C. Melting curve was assessed at 
65°C–95°C (in 0.5°C increments) at each 5 sec/step. The 
expression levels were normalized to beta-actin by the 
delta-CT method, and the data are the relative expression. 
Results are presented as the mean ± SD of three indepen-
dent experiences in triplicate.
Western Blotting
For each cell line, 20 µg of protein was loaded onto poly-
acrylamide gels, separated by SDS-PAGE and electropho-
retically transferred into nitrocellulose membranes. Blots 
were blocked with 5% milk for 2 hr at room temperature and 
protein was detected by overnight incubation (4°C) using 
rabbit anti-human SPINT2 antibody (1:1000, HPA011101; 
Sigma-Aldrich, St. Louis, MO). After washing, the mem-
branes were incubated for 1 hr at room temperature with 
horseradish peroxidase–conjugated secondary antibody 
(1:5000; Santa Cruz Biotechnology, Dallas, TX). As a load-
ing control, glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) protein expression was detected using mouse 
anti-human monoclonal GAPDH antibody (1:2000; 
sc-69778, Santa Cruz Biotechnology). Blot detection was 
performed using chemiluminescence (ECL Western Blotting 
Detection Reagents; GE Healthcare, Buckinghamshire, UK) 
and a Chemidoc (Bio-Rad).
Bisulfite Genomic Sequencing
DNA isolated from PCa (22RV1) and medulloblastoma 
(UW228) cell lines was treated with sodium bisulfite using 
the EZ DNA Methylation Golf Kit (Zymo Research 
Corporation; Irvine, CA) according to the manufacturer’s 
instructions. After treatment, the DNA promoter region of 
SPINT2 gene was amplified by touchdown PCR using 
primers already described (Dong et al. 2010) that cover 85 
CpG sites of the SPINT2 promoter region. PCR products 
were gel-purified and Sanger sequenced (STABVIDA ser-
vices) to determine SPINT2 methylation status.
Methylation-specific PCR (MSP) Analysis
DNA isolated from FFPE PCa tissue, as previously described 
(Viana-Pereira et al. 2011), or PCa cell lines, as previously 
described (Moniz et al. 2013), was treated with sodium 
bisulfite using the EZ DNA Methylation Golf Kit (Zymo 
Research Corporation) according to the manufacturer’s 
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instructions. Methylation of the SPINT2 promoter was deter-
mined by methylation-specific PCR (MSP), performed as 
previously described (Morris et al. 2005; Kongkham et al. 
2008). This region was amplified using two sets of primers 
that were designed and validated by bisulfite sequencing to 
amplify either methylated or unmethylated promoters of 
bisulfite-modified DNA. In a total reaction volume of 20 µl 
was 1 µl of DNA, 1× incomplete buffer (Invitrogen), 1.5 
mM of MgCl
2
 (Invitrogen), 200 µM of dNTPs (Invitrogen), 
0.2 µM of each primer and 1 U of Taq Platinum (Invitrogen). 
PCR cycling conditions were denaturation for 5 min at 
95°C, followed by 38 cycles of 45 sec at 95°C (denatur-
ation), 45 sec at 60°C (annealing) and 45 sec at 72°C 
(extension). The melanoma cell line (WM9) and blood were 
used as methylated and unmethylated SPINT2 promoter 
controls, respectively.
5-Aza-2’-Deoxycytidine Treatment
The four PCa cell lines (22RV1, LNCaP, PC3 and DU145) 
and the control melanoma cell line (WM9), which is known 
to bear a hypermethylated SPINT2 promotor, were treated 
with the demethylation agent 5-aza-2’-deoxycytidine 
(5-aza) (Sigma-Aldrich). Briefly, 3×105 cells/well were 
seeded onto 6-well plates and grown in RPMI medium sup-
plemented with 10% FBS and 1% penicillin-streptomycin. 
Cells were treated with 5 µM of 5-aza for 72 hr, with 
medium and 5-aza replaced every 24 hr. As a control, cell 
lines were treated with DMSO. After treatment, SPINT2 
methylation status and mRNA SPINT2 expression were 
evaluated by MSP and RT-qPCR, respectively.
SPINT2 Immunohistochemistry
Tissue microarray (TMA) blocks were constructed to contain 
three representative areas of each PCa (1-mm diameter core) 
and adjacent non-neoplastic tissues. Immunohistochemical 
staining was applied using the anti-human SPINT2 antibody 
(1:500, HPA011101, Sigma-Aldrich) and the streptavidin-
biotin peroxidase complex system (UltraVision Large 
Volume Detection System Anti-Polyvalent, HRP; LabVision 
Corporation, Fremont, CA), according to the manufacturer’s 
instructions.
The level of SPINT2 staining was semi-quantitated by 
intensity scoring: 0, negative; 1, weak; 2, moderate; 3, strong 
(Bergum et al. 2010; Martinho et al. 2012; Martinho et al. 
2013). Tumor tissues that presented scores between 0 and 1 
were classified as negative for SPINT2 staining, those that 
were scored as 2 demonstrated moderate positive staining, 
and those scoring 3 as strongly positive. Placental and muscle 
tissues were used as positive and negative controls, respec-
tively. Additionally, the primary antibody was omitted from 
the staining as another negative control. Images were taken in 
Nikon Eclipse 50i Y-THM microscope (Nikon; Tokyo, Japan).
In silico Analysis
SPINT2 mRNA levels were retrieved from Oncomine 
database (Rhodes et al. 2007; http://www.oncomine.org). 
Ten prostate samples datasets were assessed: Grasso (28 
prostate gland, 59 PCa, 35 metastasis) (Grasso et al. 2012); 
Tomlins (28 prostate gland, 30 PCa, 19 metastasis) 
(Tomlins et al. 2005); Taylor (29 prostate gland, 131 PCa, 
19 metastasis) (Taylor et al. 2010); Yu (23 prostate gland, 
64 PCa, 24 metastasis) (Yu et al. 2004); Lapointe (41 pros-
tate gland, 62 PCa, 8 metastasis) (Lapointe et al. 2004); 
Singh (50 prostate gland, 52 PCa) (Singh et al. 2009); 
Holzbeierlein (4 prostate gland, 40 PCa, 9 metastasis) 
(Holzbeierlein et al. 2004); LaTulippe (3 prostate gland, 
23 PCa, 9 metastasis) (LaTulippe et al. 2002); Chandran 
(10 PCa, 21 metastasis) (Chandran et al. 2007); and Vanaja 
(8 prostate gland, 27 PCa, 5 metastasis) (Vanaja et al. 
2003). SPINT2-negative and SPINT2-positive patients 
were categorized based on the median-centered intensity 
values of SPINT2 probes.
SPINT2 promoter methylation was evaluated using seven 
specific methylation probes (cg10154122, cg27176870, 
cg18354742, cg15375239, cg19337852, cg16655905 and 
cg23090870) collected from TCGA (https://www.tcga-data.
nci.nih.gov/tcga) database, and comprised 201 patients. For 
all probes, intensity values greater than 0.5 were considered 
methylated and intensity values less than or equal to 0.5 
were considered non-methylated.
Statistical Analysis
Pearson’s Chi-Square (χ2) test was carried out using SPSS 
19.0 (SPSS Inc., Chicago, IL) to evaluate the correlation 
between SPINT2 expression and clinical characteristics. 
For in silico analysis, a one-way ANOVA was used to com-
pare SPINT2 expression among normal, PCa, and metasta-
sis samples using GraphPad Prism software version 6 
(GraphPad Software, La Jolla, CA). A two-way ANOVA 
(Bonferroni’s post-hoc test) was used to compare mRNA 
expression levels before and after 5-aza treatment. The 
threshold used for statistical significance was p<0.05.
Results
Expression of SPINT2 Protein in Prostate Tissues
The expression of SPINT2 protein was analyzed by 
immunohistochemistry in a total of 57 patients; yet, due 
to technical issues, we could only obtain immunostaining 
results in 45 PCa and 52 adjacent non-neoplastic tissues 
(Fig. 1). Because only three samples—two non-neoplas-
tic and one PCa—were classified as SPINT2 negative 
with a score of 0 or 1, we have grouped these samples 
with the moderate positive cases (score 2) and sub-divided 
the staining as low/intermediate (score 0–2) and high 
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(score 3) expression. SPINT2 staining was exclusively 
detected in the prostatic acini, in the cytoplasm, and in the 
membrane of cells. In most samples, PCa presented 
weaker and less diffuse staining than normal parenchyma. 
We observed a significant reduction in the level of 
SPINT2 expression (high vs low/intermediate staining) 
from non-neoplastic to tumor tissues (43/52 (83%) low 
staining to 28/45 (62%) high staining, respectively; 
p=0.038; Fig. 1A and 1F). No significant association 
among the SPINT2 protein expression and clinicopatho-
logical parameters was observed (Table 1). Analysis of 
mRNA (Fig. 2A) and protein (Fig. 2B) expression in PCa 
cell lines showed that the majority of cell lines exhibited 
SPINT2 expression.
Figure 1. Staining for SPINT2 protein expression in non-neoplastic prostate and prostate carcinoma tissues. (A) Adjacent non-
neoplastic prostate (intensity score 3); Prostate carcinoma exhibiting (B) strong staining (intensity score 3), (C) moderate staining 
(intensity score 2), and (D) weak staining (intensity score 1). (E) High magnification of SPINT2 staining shows SPINT2 localization in 
the membrane and cytoplasm. (F) Comparison between the percentage of non-neoplastic and neoplastic prostate tissues with high 
and low/intermediate SPINT2 expression. SPINT2 expression is reduced in prostate carcinoma. *p<0.05; **p<0.01; ***p<0.001. Scale 
(A–D) 50 µm; (E) 20 µm.
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SPINT2 Promoter Hypermethylation Analysis in 
Prostate Carcinoma
We were able to evaluate the methylation status of SPINT2 
by MSP in 55 of 57 primary PCa samples using specific 
primers for CpG island 5’ of the transcriptional start of 
SPINT2. In this analysis, we found that none of the cases 
presented SPINT2 promoter methylation (Fig. 3). Similar 
findings were observed in PCa cell lines (Fig. 3).
In order to clarify whether the methylation status was 
absent in the SPINT2 promoter, we performed bisulfite 
sequencing using the 22RV1 cell line, together with the 
SPINT2 methylated control cell line (UW228). We verified 
that all of the 46 CpG sites sequenced in the UW228 cell 
line SPINT2 promoter were methylated (data not shown). In 
contrast, in the 22RV1 cell line, none of the 60 CpG sites 
sequenced in SPINT2 promoter region were methylated 
(data not shown). In addition, to confirm that methylation 
status does not affect SPINT2 expression, we treated the 
four PCa cell lines, together with a melanoma cell line 
known to have promoter methylation (WM9), with a 
demethylating agent 5-Aza-2’-Deoxycytidine (5 µM). After 
treatment, we verified that SPINT2 promoter remains 
unmethylated in the PCa cells (Fig. 4A) and that the inhibi-
tion of DNA methyltransferases had no significant effect on 
Table 1. Associations among SPINT2 Protein Expression and Clinicopathological Parameters.
SPINT2
 N
Low/Intermediate 
Expression (%)
High Expression 
(%) p Value
Age
 ≤63 20 9 (45.0) 11 (55.0) 0.537
 >63 25 8 (32.0) 17 (68.0)
Gleason Score
 Low (4–6) 15 3 (20.0) 12 (80.0) 0.218
 Intermediate (7) 26 12 (46.2) 14 (53.8)
 High (8–9) 4 2 (50.0) 2 (50.0)
PSA
 ≤6 6 3 (50.0) 3 (50.0) 1.000
 >6 22 9 (40.9) 13 (59.1)
Biochemical Recurrence
 No 43 16 (37.2) 27 (62.8) 1.000
 Yes 2 1 (50.0) 1 (50.0)
Capsular Invasion
 No 10 6 (60.0) 4 (40.0) 0.143
 Yes 35 11 (31.4) 24 (62.2)
Perineural Invasion
 No 14 5 (35.7) 9 (64.3) 1.000
 Yes 31 12 (38.7) 19 (61.3)
Lymph nodes Invasion
 No 38 15 (39.5) 23 (60.5) 0.693
 Yes 7 2 (28.6) 5 (71.4)
Extra-Prostatic Invasion
 No 36 13 (36.1) 23 (63.9) 0.711
 Yes 9 4 (44.4) 5 (55.6)
Vascular Invasion
 No 43 16 (37.2) 27 (62.8) 1.000
 Yes 2 1 (50.0) 1 (50.0)
Figure 2. SPINT2 expression characterization in prostate cancer 
cell lines. (A) Detection of mRNA expression by RT-qPCR. (B) 
Detection of protein expression by western blot.
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the SPINT2 gene expression in the PCa cell lines, in con-
trast to the control-methylated cell line (Fig. 4B).
In silico Analysis of SPINT2 in Prostate Tissue
Using the bioinformatics tool Oncomine (Rhodes et al. 2007; 
www.oncomine.org), we explored the expression of SPINT2 
mRNA in 885 cases from ten different datasets. From Grasso 
(122 samples), Tomlins (101 samples), Taylor (179 samples) 
and Holzbeierlein (53 samples) datasets, we observed no sta-
tistical differences in SPINT2 mRNA expression among the 
normal, primary PCa and metastatic tissues (Fig. 5). 
Moreover, Yu (111 samples), Lapointe (111 samples), Singh 
(102 samples) and LaTulippe (35 samples) datasets demon-
strated an increase in SPINT2 mRNA levels from normal 
prostate gland to PCa and metastatic samples (Fig. 5). Also in 
Yu and Lapointe datasets, the highest levels of SPINT2 were 
associated with the presence of metastasis (Fig. 5). In con-
trast, the Chandran (31 samples) and Vanaja (40 samples) 
datasets showed that the lowest levels of SPINT2 were asso-
ciated with the presence of metastasis (Fig. 5).
Additionally, we further characterized the methylation 
status of SPINT2. For this, we analyzed the TCGA (www.
tcga-data.nci.nih.dov) dataset comprising 201 patients diag-
nosed with PCa. All seven probes that recognize the SPINT2 
promoter region (cg10154122, cg27176870, cg18354742, 
cg15375239, cg19337852, cg16655905 and cg23090870) 
showed an absence of SPINT2 promoter hypermethylation 
(Fig. 6).
Discussion
The ability of serine proteases to degrade the extracellular 
matrix is essential for PCa progression (Bok et al. 2003; 
Klezovitch et al. 2004). SPINT2 is a kunitz-type serine pro-
tease inhibitor, in which the Kunitz domains are responsible 
for its inhibitory activity. The SPINT2 protein is thought to 
be first produced in a membrane-associated form and then 
released from cells by ectodomain shedding through pro-
teolytic cleavage in a COOH-terminally truncated form 
(Kawaguchi et al. 1997; Shimomura et al. 1997; Qin et al. 
1998). SPINT2 displays an inhibitory activity in secreted 
proteases (HGFA and plasmin), as well as in membrane ser-
ine proteases (hepsin and matriptase) (Delaria et al. 1997; 
Marlor et al. 1997; Qin et al, 1998; Szabo et al. 2008). Tsai 
et al. (2013) demonstrated that SPINT2 losses are associ-
ated with PCa cell invasion and metastatic capacity. 
Moreover, the authors showed that SPINT2 regulates mat-
riptase activity, in that its presence is associated with the 
inhibition of matriptase activation and the consequent 
reduction in MET signaling, PCa cell migration and inva-
sion (Tsai et al. 2013).
Figure 3. SPINT2 promoter methylation analysis. Representative example of methylation-specific PCR for SPINT2 in prostate carcinoma 
tissue and cell lines. WM9 cell line and blood were used as SPINT2 -methylated and -unmethylated controls, respectively. M, product 
from methylated DNA (162 bp) and UM, from unmethylated DNA (168 bp).
Figure 4. SPINT2 expression analysis after treatment with 
the demethylation agent 5-aza. 5-aza treatment was performed 
in PCa cell lines: 22RV1, LNCap, PC3 and DU145. (A) SPINT2 
methylation status before and after 5-aza demethylation 
treatment, as determined using MSP. (B) Detection of the SPINT2 
expression levels by qPCR before and after 5-aza treatment. 
WM9 cell line was used as positive control for the methylated 
SPINT2 promoter. *p<0.05; **p<0.01; ***p<0.001.
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In the current study, we observed a decrease in immuno-
histochemistry intensity of SPINT2 between non-neoplastic 
and neoplastic prostate tissues. This result is in accordance 
with previous studies that showed a significant decrease in 
SPINT2 protein expression in malignant prostate tissues as 
compared with normal glands, with the lowest levels of 
expression found in the most undifferentiated of the pros-
tate tumors (with higher Gleason score) (Bergum et al. 
2010; Tsai et al. 2013). The lack of an association between 
SPINT2 and Gleason score in our cohort might be justified 
for the limited number of evaluated patients. Our immuno-
histochemical results were in agreement with Chandran 
(Chandran et al. 2007) and Vanaja (Vanaja et al. 2003) data-
sets, which reported that the loss of SPINT2 mRNA levels is 
associated with metastasis formation. The mRNA expres-
sion profiles among the other eight Oncomine datasets are 
not in agreement.
In several tumor types, the mechanism underlying 
SPINT2 downregulation is gene promoter hypermethylation 
(Fukai et al. 2003; Chiba et al. 2005; Morris et al. 2005; 
Kongkham et al. 2008; Morris et al. 2008; Schuster et al. 
2003; Tung et al. 2009; Dong et al. 2010). Therefore, we 
analyzed, for the first time, the possibility of this epigenetic 
regulation in PCa. We verified that none of the 55 cases in 
our cohort or in the 4 PCa cell lines we studied presented 
SPINT2 promoter methylation. In addition, none of the 201 
cases in the TCGA cohort showed SPINT2 promoter meth-
ylation. In the cell lines, we validated these findings by dis-
tinct methodologies, namely bisulfite sequencing and 
following treatment with the demethylating agent 5-Aza-2’-
Deoxycytidine. These two techniques showed the absence of 
SPINT2 promoter hypermethylation in prostate cancer. In 
our PCa cohort, we observed SPINT2 expression in all of the 
cases (only one PCa sample with weak staining), which is in 
accordance with the observed unmethylated status of the 
SPINT2 promoter. However, the mechanism involved in the 
different expression intensity between normal and neoplas-
tic tissues remains to be determined. Morris and collabora-
tors demonstrated that, in addition to the frequent 
methylation of SPINT2 promoter in renal cell carcinoma, a 
Figure 5. In silico analysis of SPINT2 levels from the Oncomine database. SPINT2 mRNA level distribution among prostate gland, 
primary carcinoma and metastatic tissues in ten Oncomine datasets (885 samples). *p<0.05; **p<0.01; ***p<0.001.
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nonconservative missense substitution was detected. 
However, they showed that this mutation did not lead to a 
reduction in SPINT2 expression but led to reduced tumor 
suppressor function (Morris et al. 2005). We have confirmed 
that SPINT2 protein is decreased in PCa but the levels of 
mRNA were not consistent neither among the various datas-
ets nor compared to protein levels. Therefore, it is plausible 
to consider that post-translational alterations may occur. 
SPINT2 is a glycosylated protein, potentially containing 2 
N- and 5 O-glycosylation sites (Kawaguchi et al. 1997; 
Steentoft et al. 2013). Glycosylation alterations are very fre-
quent in cancer, and have been shown to be involved with 
cancer development and progression (Stowell et al. 2015). A 
possible deregulation of the mechanism of glycosylation 
may lead to a SPINT2 misfolding, which can undergo ubiq-
uitination and posterior degradation of the protein.
In conclusion, our results suggest a downregulation of 
SPINT2 in PCa tumorigenesis, potentially associated with 
post-translational mechanisms.
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